These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 4070930)

  • 41. The influence of the extent of target organs on sensitivities of methods for screening rodent carcinogens.
    Fu ZD; Chen WR; Gu LJ; Gu ZW
    Mutat Res; 1995 Sep; 331(1):99-117. PubMed ID: 7666873
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Experimental investigations with anti-cancer drugs for carcinogenicity with special reference to immunedepression.
    Schmähl D
    Recent Results Cancer Res; 1975; (52):18-28. PubMed ID: 1234999
    [No Abstract]   [Full Text] [Related]  

  • 43. Neonatal mouse model: review of methods and results.
    McClain RM; Keller D; Casciano D; Fu P; MacDonald J; Popp J; Sagartz J
    Toxicol Pathol; 2001; 29 Suppl():128-37. PubMed ID: 11695548
    [TBL] [Abstract][Full Text] [Related]  

  • 44. NTP technical report on the toxicology and carcinogenesis studies of Elmiron (Cas No. 37319-17-8) in F344/N rats and B6C3F1 mice (Gavage Studies).
    National Toxicology Program, Public Health Services, National Institutes of Health, US Department of Health and Human Services,
    Natl Toxicol Program Tech Rep Ser; 2004 May; (512):7-289. PubMed ID: 15213766
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens.
    French J; Storer RD; Donehower LA
    Toxicol Pathol; 2001; 29 Suppl():24-9. PubMed ID: 11695559
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relevance of short-term carcinogenicity tests to the study of the carcinogenic potential of urban air.
    Harnden DG
    Environ Health Perspect; 1978 Feb; 22():67-70. PubMed ID: 648491
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of rodent carcinogens by an expert system.
    Rosenkranz HS; Klopman G
    Prog Clin Biol Res; 1990; 340B():23-48. PubMed ID: 2203007
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An assessment of the carcinogenic potential of ezetimibe using nonclinical data in a weight-of-evidence approach.
    Halleck M; Davis HR; Kirschmeier P; Levitan D; Snyder RD; Treinen K; Macdonald JS
    Toxicology; 2009 Apr; 258(2-3):116-30. PubMed ID: 19428931
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An overview of short-term tests for the mutagenic and carcinogenic potential of pesticides.
    Waters MD; Simmon VF; Mitchell AD; Jorgenson TA; Valencia R
    J Environ Sci Health B; 1980; 15(6):867-906. PubMed ID: 7002991
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mutagenicity, carcinogenicity and teratogenicity of cobalt metal and cobalt compounds.
    Léonard A; Lauwerys R
    Mutat Res; 1990 Jul; 239(1):17-27. PubMed ID: 2195331
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictability of human carcinogenicity from animal studies.
    Dybing E
    Regul Toxicol Pharmacol; 1986 Dec; 6(4):399-415. PubMed ID: 3101146
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Carcinogenicity, mutagenicity and teratogenicity of manganese compounds.
    Gerber GB; Léonard A; Hantson P
    Crit Rev Oncol Hematol; 2002 Apr; 42(1):25-34. PubMed ID: 11923066
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative carcinogenicity of ring-halogenated 3-methyl-1-phenyltriazenes and their 3,3-dimethyl analogs at equimolar dose levels in male Sprague-Dawley rats.
    Berger MR; Kolar GF
    J Cancer Res Clin Oncol; 1986; 111(2):129-32. PubMed ID: 3700457
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mutagenicity, carcinogenicity and teratogenicity of antimony compounds.
    Léonard A; Gerber GB
    Mutat Res; 1996 Oct; 366(1):1-8. PubMed ID: 8921983
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chronological supplement to the Carcinogenic Potency Database: standardized results of animal bioassays published through December 1982.
    Gold LS; de Veciana M; Backman GM; Magaw R; Lopipero P; Smith M; Blumenthal M; Levinson R; Bernstein L; Ames BN
    Environ Health Perspect; 1986 Aug; 67():161-200. PubMed ID: 3530736
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Carcinogenic, teratogenic, and mutagenic effects of arsenic.
    Bencko V
    Environ Health Perspect; 1977 Aug; 19():179-82. PubMed ID: 908296
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comments on the carcinogenic, mutagenic, and teratogenic properties of anticancer drugs.
    Muggia FM; Ziegler J
    Recent Results Cancer Res; 1980; 74():306-11. PubMed ID: 7444147
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Carcinogen prediction in the laboratory: a personal view.
    Garner RC
    Proc R Soc Lond B Biol Sci; 1979 Jul; 205(1158):121-34. PubMed ID: 40233
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mutagenicity, carcinogenicity and teratogenicity of lithium compounds.
    Léonard A; Hantson P; Gerber GB
    Mutat Res; 1995 Oct; 339(3):131-7. PubMed ID: 7491123
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Second chronological supplement to the Carcinogenic Potency Database: standardized results of animal bioassays published through December 1984 and by the National Toxicology Program through May 1986.
    Gold LS; Slone TH; Backman GM; Magaw R; Da Costa M; Lopipero P; Blumenthal M; Ames BN
    Environ Health Perspect; 1987 Oct; 74():237-329. PubMed ID: 3691431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.